Brevan Howard Capital Management LP Black Diamond Therapeutics, Inc. Transaction History
Brevan Howard Capital Management LP
- $12.7 Billion
- Q1 2024
A detailed history of Brevan Howard Capital Management LP transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 29,050 shares of BDTX stock, worth $128,982. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,050Holding current value
$128,982% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BDTX
# of Institutions
93Shares Held
36.5MCall Options Held
29.6KPut Options Held
5K-
Bellevue Group Ag Kuesnacht, V88.52MShares$37.8 Million0.68% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.73MShares$29.9 Million0.02% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$19.8 Million1.58% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.91MShares$8.46 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.6MShares$7.12 Million0.99% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $161M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...